Qiagen enhances GeneReader NGS system
Jan. 20, 2017—Qiagen announced a comprehensive range of enhancements for the GeneReader NGS system, in particular the launch of gene panels that will create a full menu for oncology applications. The company plans to commercialize at least five new GeneRead QIAact gene panels during the year, many of which are compatible with both formalin-fixed, paraffin-embedded tissue samples and noninvasive liquid biopsies. Other enhancements include customized panels and related workflows, a broader range of mutation analysis, increased sample processing capacity, and new proprietary sequencing chemistry.
The company also announced it achieved its target for placing 55 to 60 GeneReader NGS systems with customers worldwide at the end of 2016, following the start of commercialization in late 2015. This represents more than a 10 percent share of the estimated worldwide annual market for new placements of benchtop sequencer used for oncology applications, according to the company.
“We are very pleased with the response of customers to the GeneReader NGS System, which has confirmed our strategic decision to provide a simpler, more cost-effective way for any laboratory worldwide to take advantage of NGS technology and improve outcomes,” Peer M. Schatz, chief executive officer of Qiagen N.V., said in a company statement. “This comprehensive range of enhancements will further differentiate the GeneReader NGS System and help customers explore the expanding content menu and ability to gain valuable molecular insights. We look forward to further expanding and enhancing the utility, efficiency, and cost-effectiveness of this truly differentiated Sample to Insight solution and our NGS portfolio.”